Lupin receives European Commission approval for biosimilar ranibizumab Ranluspec
Published on 23/02/2026 04:14 PM
Lupin receives European Commission approval for biosimilar ranibizumab RanluspecShares of Lupin Ltd ended at ₹2,250.55, up by ₹30.85, or 1.39%, on the BSE.By Jomy Jos Pullokaran February 23, 2026, 4:14:52 PM IST (Published)2 Min ReadDrug firm Lupin Ltd on Monday (February 23) announced that it has received approval from the European Commission for its biosimilar ranibizumab, Ranluspec (for vials and pre-filled syringes).
The approval follows a recent positive opinion from the Committee for Medicinal Products for Human Use. Ranibizumab is a recombinant humanised IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A).
Its indications include the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, proliferative diabetic retinopathy, and choroidal neovascularisation.
Also Read: Lupin Q3 Results: Net profit up 38% on US sales surge and divestment gains
Thierry Volle, President EMEA and Emerging Markets, Lupin, said, "We are very pleased to receive the European Commission approval for ranibizumab. This achievement underscores the strength and quality of our scientific capabilities and manufacturing excellence. We remain firmly committed to expanding access to innovative, high-quality, and affordable biologic therapies for underserved patients worldwide."
Dr Cyrus Karkaria, President of Biotechnology, Lupin, said, "The approval from the European Commission for our biosimilar ranibizumab is a milestone that validates our unwavering commitment and scientific standards to making advanced biologic therapies more accessible.
Lupin’s biosimilar ranibizumab will be commercialised by Sandoz across the European Union (excluding Germany). In France, the product will be commercialised by two companies, Sandoz and Biogaran."
Also Read: Lupin shares may see up to 16% upside post Q3, analysts say — should you buy?
Shares of Lupin Ltd ended at ₹2,250.55, up by ₹30.85, or 1.39%, on the BSE.Continue Reading(Edited by : Jomy Jos Pullokaran)TagsLupinshare market today